SCHEMBL4436742

SCHEMBL4436742

CCOC(=O)C(Cc1cccc(C(F)(F)F)c1)C(C)=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 3/20 0.51
HTR2B P41595 3/20 0.51
HTR2C P28335 2/20 0.51
THRB P10828 1/20 0.51
MAPT P10636 3/20 0.49
ADRA2C P18825 2/20 0.49
SLC6A4 P31645 2/20 0.49
ADRA1A P35348 2/20 0.49
DRD3 P35462 2/20 0.49
SIGMAR1 Q99720 1/20 0.49
LMNA P02545 1/20 0.49
OPRK1 P41145 1/20 0.49
USP2 O75604 2/20 0.48
CYP3A4 P08684 2/20 0.48
NR1I2 O75469 1/20 0.48
ADRB1 P08588 1/20 0.48
HTR1A P08908 1/20 0.48
ADRA2A P08913 1/20 0.48
ADORA3 P0DMS8 1/20 0.48
ADRA2B P18089 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6714650 0.93 HTR2A (0.55) HTR2AHTR2BHTR2CTHRBMAPT
SCHEMBL30589450 0.93 HTR2A (0.55) HTR2AHTR2BHTR2CTHRBMAPT
SCHEMBL16571756 0.88 HTR2A (0.50) HTR2AHTR2BHTR2CTHRBMAPT
SCHEMBL6691789 0.87 HTR2A (0.61) HTR2AHTR2BHTR2CMAPTADRA2C
SCHEMBL15262748 0.87 THRB (0.49) HTR2AHTR2BHTR2CTHRBMAPT
SCHEMBL7058689 0.87 THRB (0.49) HTR2AHTR2BHTR2CTHRBMAPT
SCHEMBL2428054 0.86 GPR35 (0.41) THRBMAPTLMNACYP3A4CYP1A2
SCHEMBL20543990 0.85 HTR2A (0.60) HTR2AHTR2BHTR2CTHRBMAPT
SCHEMBL15262515 0.84 ALDH1A1 (0.50) HTR2AHTR2BHTR2CTHRBMAPT
SCHEMBL15246756 0.83 PPARG (0.54) MAPTMAOBALDH1A1KDM4ENPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11851435-B2 PTGR2 inhibitors and their use NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2023-12-26 US disclosed
US-20230279008-A1 PTGR2 INHIBITORS AND THEIR USE NATIONAL TAIWAN UNIVERSITY (TW) 2023-09-07 US disclosed
CN-101801972-A Pyrazolo [1,5-A]pyrimidines as inhibitors of stearoyl-coA desaturase INOVACIA AB 2010-08-11 CN disclosed
EP-2137187-A1 PYRAZOLO [1,5-A]PYRIMIDINES AS INHIBITORS OF STEAROYL-COA DESATURASE Inovacia AB (SE) 2009-12-30 EP disclosed
US-20080255153-A1 New compounds BIOVITRUM AB (PUBL) (SE) 2008-10-16 US disclosed
US-20080255153-A1 New compounds BIOVITRUM AB (PUBL) (SE) 2008-10-16 US disclosed
US-20080255153-A1 New compounds BIOVITRUM AB (PUBL) (SE) 2008-10-16 US disclosed
WO-2008116898-A1 PYRAZOLO [1,5-A]PYRIMIDINES AS INHIBITORS OF STEAROYL-COA DESATURASE BIOVITRUM AB (PUBL) (SE) 2008-10-02 WO disclosed
WO-2008116898-A1 PYRAZOLO [1,5-A]PYRIMIDINES AS INHIBITORS OF STEAROYL-COA DESATURASE BIOVITRUM AB (PUBL) (SE) 2008-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11851435-B2 PTGR2 inhibitors and their use PTGFR, PTGIR, PTGDR2 HTR2A 214/4885HTR2B 256/4885HTR2C 341/4885
US-20230279008-A1 PTGR2 INHIBITORS AND THEIR USE PTGFR, PTGIR, PTGDR2 HTR2A 214/4885HTR2B 256/4885HTR2C 341/4885
US-20080255153-A1 New compounds SCD, SCD5, FADS2 HTR2A 4566/4885HTR2B 4619/4885HTR2C 4625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.